LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today provided a comprehensive scientific update on its acute care product pipeline, which is advancing aggressively behind the company’s successful and growing IV antibiotic CUBICIN® (daptomycin for injection). In an investor presentation web cast from the Back Bay Events Center in Boston, MA, a team of senior Cubist scientists led by the company’s Chief Scientific Officer, Steve Gilman, Ph.D., reviewed scientific/clinical data and upcoming milestones for four programs, one in Phase 2 and three pre-IND, each addressing significant unmet medical need.
